Assessing the Psychosocial and Financial Impact of CAR-T on Survivors and Caregivers

Overview

About this study

Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are unknown. In addition, relatively little is known about the psychosocial impact of CAR-T on survivors and their caregivers. Due to the intensive nature of CAR-T treatment and its unique side effects, including neurotoxicity in the acute setting and infections and financial burden in the long-term setting, a longitudinal study that assesses these issues in a quantitative and qualitative fashion is required. Consideration of both patient and caregiver needs is important for the provision of appropriate and effective health services, particularly in intensive cancer treatments that require a caregiver, such as CAR-T.

Our objective in this proposal is to define the long-term needs of CAR-T survivors using patient-reported health-related quality of life (QOL) measures, qualitative interviews, and adverse event data. The rationale for our proposed study is that it will provide the necessary knowledge on CAR-T survivor physical, mental, and social health to formulate a CAR-T specific survivorship program that can be implemented and studied in the future.

We aim to recruit 100 subjects (50 survivors and 50 caregivers) to the study. Inclusion Criteria are the following:  age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able to complete a written questionnaire in English either independently or with assistance, and able to perform a verbal interview either in person or via phone teleconference. We will survey patients at baseline and then at pre-specified timepoints up to 2 years after CAR-T. Survey questionnaires that have been previously validated in cancer populations will be used to assess: overall quality of life, psychosocial impact, cognitive function, post-traumatic stress, spiritual well-being, and financial toxicity. Patient demographics, adverse events, and comorbidities will also be collected via survey and/or medical record review. A selected subset of participants (10 survivors and 10 caregivers) will be chosen to undergo semi-structured open ended interviewing to obtain a qualitative understanding of unmet needs, social support, and distress. Data will be analyzed and compared to historical lymphoma and transplant cohorts.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18.
  • Blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma).
  • Receiving a CAR-T product.
  • Able to complete a written questionnaire in English either at home or with assistance at an appointment.
  • Able to perform a verbal interview either in person or via phone teleconference.

Exclusion Criteria:

  • Severe cognitive deficit of neuropsychiatric condition that would prevent person from being able to provide informed consent or complete survey or interview questions.

Eligibility last updated 6/3/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Urshila Durani, M.D., M.P.H.

Contact us for the latest status

Contact information:

Yi Lin M.D., Ph.D.

(507) 284-5096

Lin.Yi@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Urshila Durani, M.D., M.P.H.

Contact us for the latest status

Contact information:

Urshila Durani M.D., M.P.H.

(507) 284-2511

Durani.Urshila@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Urshila Durani, M.D., M.P.H.

Open for enrollment

Contact information:

Yi Lin M.D., Ph.D.

(507) 284-5096

Lin.Yi@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20526690

Mayo Clinic Footer